Capital Management Corp VA Purchases New Holdings in Exelixis, Inc. (EXEL)

Capital Management Corp VA purchased a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 285,575 shares of the biotechnology company’s stock, valued at approximately $5,060,000.

Other large investors have also recently added to or reduced their stakes in the company. Janney Montgomery Scott LLC lifted its holdings in Exelixis by 31.2% during the 2nd quarter. Janney Montgomery Scott LLC now owns 17,220 shares of the biotechnology company’s stock worth $371,000 after purchasing an additional 4,095 shares during the last quarter. American Century Companies Inc. lifted its holdings in Exelixis by 504.6% during the 2nd quarter. American Century Companies Inc. now owns 2,034,270 shares of the biotechnology company’s stock worth $43,777,000 after purchasing an additional 1,697,822 shares during the last quarter. First Trust Advisors LP lifted its holdings in Exelixis by 78.6% during the 3rd quarter. First Trust Advisors LP now owns 4,643,726 shares of the biotechnology company’s stock worth $82,287,000 after purchasing an additional 2,044,201 shares during the last quarter. Retirement Systems of Alabama acquired a new stake in Exelixis during the 2nd quarter worth approximately $7,692,000. Finally, Schwab Charles Investment Management Inc. lifted its holdings in Exelixis by 4.9% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 1,019,297 shares of the biotechnology company’s stock worth $21,936,000 after purchasing an additional 47,730 shares during the last quarter. 80.87% of the stock is owned by institutional investors and hedge funds.

Several analysts recently weighed in on EXEL shares. Guggenheim started coverage on Exelixis in a report on Monday, September 17th. They set a “buy” rating for the company. Goldman Sachs Group started coverage on Exelixis in a report on Monday, September 17th. They set a “neutral” rating and a $22.00 price target for the company. Morgan Stanley started coverage on Exelixis in a report on Monday, September 10th. They set an “underweight” rating and a $19.00 price target for the company. BidaskClub raised Exelixis from a “strong sell” rating to a “sell” rating in a report on Thursday, August 30th. Finally, Stifel Nicolaus dropped their price target on Exelixis from $29.00 to $25.00 and set a “hold” rating for the company in a report on Wednesday, August 1st. Three research analysts have rated the stock with a sell rating, two have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $29.78.

Shares of NASDAQ EXEL opened at $13.87 on Thursday. The firm has a market capitalization of $4.21 billion, a price-to-earnings ratio of 27.20 and a beta of 1.93. Exelixis, Inc. has a fifty-two week low of $13.42 and a fifty-two week high of $32.20.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Wednesday, August 1st. The biotechnology company reported $0.28 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.16 by $0.12. The firm had revenue of $186.10 million during the quarter, compared to analysts’ expectations of $157.37 million. Exelixis had a return on equity of 65.68% and a net margin of 48.17%. The company’s quarterly revenue was up 88.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.06 EPS. Equities research analysts anticipate that Exelixis, Inc. will post 1.03 earnings per share for the current fiscal year.

In other Exelixis news, Director Vincent T. Marchesi sold 40,000 shares of Exelixis stock in a transaction on Wednesday, August 15th. The stock was sold at an average price of $19.50, for a total value of $780,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael Morrissey sold 100,000 shares of Exelixis stock in a transaction on Tuesday, August 7th. The shares were sold at an average price of $21.10, for a total value of $2,110,000.00. The disclosure for this sale can be found here. Insiders sold a total of 563,629 shares of company stock valued at $11,192,853 over the last ninety days. Insiders own 4.80% of the company’s stock.

Exelixis Profile

Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Further Reading: What is the 52-week high/low?

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply